Browsing Tag
trofinetide
3 posts
Neuren Pharmaceuticals (ASX: NEU) lifts 2026 royalty outlook after record DAYBUE quarter
Record DAYBUE sales and rapid adoption of its STIX formulation have strengthened Neuren Pharmaceuticals’ royalty outlook, while Europe and Japan offer the next major tests of the franchise’s global potential.
Acadia’s LOTUS study confirms long‑term benefits and manageable side‑effects of DAYBUE over 12 months in Rett syndrome
New real-world data shows DAYBUE improves Rett syndrome symptoms and is tolerable over 12 months. Find out what the LOTUS study reveals for patients and doctors.
LAVENDER phase 3 clinical trial launched for trofinetide in Rett syndrome by Acadia Pharmaceuticals
US biopharma company Acadia Pharmaceuticals has launched the LAVENDER phase 3 clinical trial to evaluate the efficacy and…